---
title: "Evvy’s $40M Series B: Catalio Backs Women’s Microbiome Data"
description: "Evvy raised a $40 million Series B led by Catalio Capital Management on September 15, 2026. Company: 100,000+ patients, 3,000 practitioners, CLIA/CLEP mNGS vaginal microbiome tests. Valuation not disclosed."
date: 2026-09-16T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-evvy-40m-series-b-catalio-womens-health
---

# Evvy’s $40M Series B: Catalio Backs Women’s Microbiome Data

> Evvy raised a $40 million Series B led by Catalio Capital Management on September 15, 2026. Company: 100,000+ patients, 3,000 practitioners, CLIA/CLEP mNGS vaginal microbiome tests. Valuation not disclosed.

**[Evvy](/startup/evvy)** raised a **$40 million** Series B on **September 15, 2026**, **led by Catalio Capital Management**. Valuation was **not disclosed**. Company claims via TechCrunch: **more than 100,000** patients served in the U.S., **about 3,000** practitioners, and what it calls the only at-home **CLIA-** and **CLEP-certified** mNGS vaginal microbiome test from a single swab ([TechCrunch](https://techcrunch.com/2026/09/15/evvy-raises-40m-as-it-seeks-to-further-womens-health-research-with-vaginal-microbiome-data/), [Fortune](https://fortune.com/2026/09/15/evvy-series-b-womens-health-vaginal-microbiome-research/)).

Evvy is not only selling a swab — it is trying to turn a **100k-patient dataset** into the missing female-biology training set for precision medicine and fertility, with Catalio (diagnostics specialist) writing the check.

## Key facts

| Field | Detail |
| --- | --- |
| Company | [Evvy](/startup/evvy) — women’s health diagnostics / microbiome |
| Financing | **$40M** Series B |
| Date | September 15, 2026 |
| Lead | Catalio Capital Management (**|
| Founders | Priyanka Jain, Laine Bruzek, Pita Navarro (2021) |
| Patients / clinicians (company) | **>100,000** patients; **~3,000** practitioners |
| Valuation / revenue | **Not disclosed** |

## Who uses the product — and for what job

**Users:** patients with vaginal health / infection / unexplained symptoms who want at-home testing; clinicians on Evvy’s network who review results and prescribe personalized care pathways.

**Job:** mail-in swab → mNGS sequencing in Evvy’s lab → clinician review → portal results with diagnosis, interpretation, and next steps (including prescription care when relevant). **EvvyAI** (launched May, per TC) translates microbiome data into guidance and routes clinical questions to humans.

Expansion: fertility / IVF-adjacent research linking vaginal microbiome to infertility, preterm birth, IVF success, and recurrent pregnancy loss — still **research-stage**, not a proven clinical product claim.

## Why now

- Female biology is under-measured in biomedical datasets; CEO framing: you cannot build precision medicine (or AI) for women on incomplete data.
- Consumer + clinician loop at **100k patients** is enough scale to pitch a **research engine**, not only a DTC test.
- Competitors (Juno Bio, Tiny Health, Daye — named in TC) keep the category visible; Evvy’s bet is **certified mNGS + clinician network + dataset**.

## Why Catalio — portfolio fit

Catalio Capital Management invests in **novel diagnostics**. Evvy’s Series B is a textbook diagnostics thesis: regulated test (CLIA/CLEP claims) + longitudinal dataset + expansion into higher-value clinical questions (fertility).

Likely reasons Catalio led (editorial judgment):

1. **Diagnostics DNA** — certified lab workflow, not a wellness quiz.
2. **Data asset** — 100k patients + peer-reviewed output claims (15 publications/abstracts per CEO to TC).
3. **Clinical channel** — 3,000 practitioners and Fortune’s note on scaling the brand into doctors’ offices.

We do **not** invent a `/fund/catalio` link. Prior investors were not fully enumerated in the TC piece we retrieved — do not invent a syndicate list.

## Competitive map

| Approach | Tradeoff |
| --- | --- |
| Symptom-only telehealth | Fast Rx; thin biology |
| Juno Bio / Tiny Health / Daye | Same category; different test/UX claims |
| Traditional clinic cultures | Standard of care; slower at-home loop |
| Evvy mNGS + clinician network | Scale + research pitch; valuation opaque |

## What is not proven

- Valuation, revenue, gross margin, or reimbursement mix.
- Clinical validity of fertility predictive claims — company says it is still compiling science.
- “Only” CLIA/CLEP mNGS positioning — company claim; verify against peers before diligence memos.
- Profitability — not disclosed.

## Practical takeaway

- **Founders (women’s health):** Pair **regulated diagnostics** with a clinician network before pitching an AI layer.
- **Investors:** Separate DTC test economics from the research/dataset story; Catalio fit is diagnostics, not consumer brand hype.
- **Clinicians / operators:** Relevant if you already see unexplained recurrent BV / fertility workups and want sequenced microbiome context.

### Sources

1. [TechCrunch — Evvy](https://techcrunch.com/2026/09/15/evvy-raises-40m-as-it-seeks-to-further-womens-health-research-with-vaginal-microbiome-data/)
2. [Fortune — Evvy](https://fortune.com/2026/09/15/evvy-series-b-womens-health-vaginal-microbiome-research/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 16, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.